279 companies scored with the Medical Devices & Diagnostics template — moat analysis optimized for medical device, instrument, and diagnostics companies.
Updated 8 days ago
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes. An instrument that runs only proprietary reagents or cartridges creates a recurring, high-margin stream a competitor cannot win without displacing the hardware and retraining the staff around it. Sustained premium gross margins are the clearest evidence that the attach rate is real.
Research spending is how a device company keeps its installed base current, but spending alone proves nothing. This defense pairs it with the returns actually earned on capital already deployed: high, durable returns say the previous generation of R&D and acquisitions produced something that lasted, which is the only real evidence the next round will too.
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash. Free cash flow is therefore the more honest measure of what the business earns. Cash flow that consistently exceeds net income indicates the charges are bookkeeping rather than economics.
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate. Commercial execution is whether that expense is scaling: an operating margin above peers, improving as revenue grows, means the same salesforce is carrying more product rather than the company buying growth.
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn. Recurring consumable revenue supports more leverage than one-off equipment sales do — but only up to the point where interest cover and net debt still leave room for the next deal or the next bad year.
Growth durability separates an expanding installed base from a good product cycle. Steady revenue growth alongside stable asset productivity suggests placements are compounding, each new instrument adding to a consumable stream that persists, rather than a single approval or tender having temporarily lifted the numbers.
iRadimed Corporation (IRMD), Electromed, Inc. (ELMD), Intuitive Surgical, Inc. (ISRG) currently hold the widest moats of the 279 companies in the group, led by iRadimed Corporation at 83 out of 100. The full ranking is on this page, and each company links through to the six defenses behind its score.
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
It scores 6 defenses: Pricing Power & Consumable Moat, R&D Pipeline & Capital Returns, FCF Quality & Cash Conversion, Commercial Execution, Capital Structure & Resilience, Growth Durability. Each is measured independently and then weighted, so a company can be strong on one and weak on another. The weights differ from other templates because the defenses that decide who wins in Medical Devices & Diagnostics are not the ones that decide it elsewhere.
Across the 279 companies in this group the median moat score is 49, with the middle half falling between 34 and 62. A score above the upper quartile puts a company in the strongest quarter of its industry. Because scores are percentile-based, roughly half of any industry sits below its own median by construction.